Dr Mahul Amin
Methodist Hospitals, Memphis, Tennessee
Dr. Mahul Amin is an internationally recognized researcher, leading urologic pathologist and highly effective operations executive, with consistent success heading up clinical practice and research transformations in translational research pathology, leading growth, and increasing industry recognition for large academic laboratories and university- based Pathology departments. Dr Amin is the Professor and Chair of the Department of Pathology and Laboratory Medicine, Professor of Urology, Gerwin Endowed Chair for Cancer Research, and Associate Director of Translational Research for the Cancer Research Centre at University of Tennessee Health Sciences Centre (UTHSC). He conducts his clinical practice as the Chief of Pathology at Methodist Le Bonheur Health System and University Clinical Health, Memphis, TN.
Dr. Amin earned his medical degree at G.S. Medical College and King Edward Memorial Hospital in Bombay, India. From 2001 to 2009, as Vice Chair and then as Chair of the Cancer Committee of the College of American Pathologists (CAP), Dr. Amin led the cause for standardized pathologic reporting of all cancer in the United States and the committees' work resulted in one of the important standards of the American College of Surgeons, Commission on Cancer center accreditation program in the United States and the CAP's laboratory accreditation program. In 2013, he was appointed as Editor-in-Chief of the 8th edition of the American Joint Committee on Cancer (AJCC) staging manual where he coordinated the activities of over 425 contributors (surgical oncologists, medical oncologists, radiation oncologists, pathologists, radiologists, cancer registrars, clinical epidemiologists and members from the cancer surveillance, computational biology and bioinformatics community) from 184 institutions, 23 countries, 5 continents to outline the next edition of cancer staging (staging manual published in October 2016). The AJCC TNM staging system is widely used in clinical decision-making of all patients with cancer, to define clinical and translational research and healthcare policy in cancer. Dr Amin is also on the Editorial board of the 8th edition UICC TNM Classification of Malignant Tumors. Due to his role in cancer staging, Dr. Amin serves as an observer to the editorial board of the WHO Blue book series.
Dr. Amin’s scientific interests are in the discovery and validation of biomarkers in urologic malignancies for clinical personalized medicine and in Artificial Intelligence applications in Pathology. He has authored 364 publications and 73 book chapters. Dr. Amin’s H Index is 107 and his i10 index is 368; his work has 67,099 citations (data from Google Scholar January 4, 2020) [among 36 new inductees in the National Academy of Sciences in biological and biomedical sciences in 2005, the median h-index was 57]. He has also co-authored 13 books (two in their second and third editions) including two Armed Forces Institute of Pathology (AFIP) fascicles, two major texts in urologic pathology and a monograph on Gleason grading of prostate cancer. Dr. Amin is a much sought of as a speaker and has given 380 pathology grand rounds, lectures and workshops. He has extensively spoken around the world and lectured in 31 countries and 75 cities outside of the US; often on multiple occasions. Dr. Amin is a co-author of the Urinary tract chapter in the world’s most widely sold medical textbook – Robbins’ Pathological Basis of Disease (10th edition – In Press). He has been a member of the national faculty for courses for the American Urology Association (AUA since 1990), United States and Canadian Academy of Pathologists (USCAP) (since 1995), American Society for Clinical Pathologists (since 1994), College of American Pathologists (since 2003) and recently American Society of Clinical Oncology (ASCO). Dr. Amin has been training fellows in Urologic Pathology since 1997 and has trained over 20 fellows many of whom are now expert uropathologists and on faculty at prestigious institutions like M.D. Anderson and Memorial Sloan Kettering Cancer Centers, Mayo Clinic, Cleveland Clinic, University of Chicago, University of Southern California etc. Trained pathologists from over 12 countries have spent time visiting and signing out cases with him.
Dr. Amin is a national and international consultant in tumors of the genitourinary tract, including prostate, urinary bladder, kidney, and testis. Dr. Amin is a world-renowned expert and educator in genitourinary pathology having co-authored the 2002 World Health Organization (WHO) classification systems for urothelial tumors and renal neoplasms (authored 7 chapters); and the 2016 WHO classification systems for tumors of the prostate, bladder, kidney, penis and testis (authored 21 chapters). He has made many significant and pioneering contributions including the first major descriptions of entities in genitourinary pathology including lymphoepithelioma-like carcinoma of the bladder, micropapillary carcinoma of the bladder, acquired cystic disease associated renal cell carcinoma, clear cell-papillary renal cell carcinoma, thyroid-like carcinoma of the kidney, tubulocystic carcinoma of the kidney, intratubular large cell hyalinizing sertoli cell neoplasia of the testis (a distinctive condition of the Peutz-Jeghers syndrome), and low-grade glandular tumors of the urachus. He has recently authored some of the first major series and descriptions on Succinate dehydrogenase - deficient renal cell carcinoma and Fumarate hydratase- deficient renal cell carcinoma, including decription of a new subtype of renal cell carcinoma - low grade oncoctytic Fumarate Hydratase deficient renal cell carcinoma. Dr. Amin was the co-first author on the new Prostate Cancer Foundation sponsored proposed classification for neuroendocrine tumors of the prostate. Dr. Amin was involved in developing the 7th (2010) edition and 8th (2017) edition of the AJCC TNM staging of prostate cancer; he was a co-organizer and co-author of the influential International Society of Urologic Pathologists Consensus Conference papers on Gleason Grading of Prostate cancer (2004 and 2014 meetings). Thus, Dr. Amin has for over two decades helped set the standards of grading and staging of prostate cancer, which are vital for appropriate management of prostate cancer patients around the world. Dr. Amin has helped bring several diagnostic markers (based on first major publications and widespread implementation) in clinical practice including CK20, p53 and CD44 in the diagnosis of flat lesions of the bladder, smoothelin in the recognition of muscularis propria of the bladder, S100p and uroplakin 2 and 3 in confirming bladder histogenesis, and kidney specific cadherin and cathepsin K in renal tumor classification.His recent interests are in Artificial Intelligence and its applications to Urologic Pathology and Anatomic Pathology work flows. Dr. Amin serves on the Executive Committee of the AJCC (2003-2011; 2013-2017), and was a member of the Genitourinary Cancer Staging Task Force, 7th Edition of AJCC staging, and lead coordinator of the prostate cancer staging system. Dr. Amin was the North American Representative to the International Society of Urologic Pathologists (ISUP) from 2012-2015 and has served on numerous committees and roles in the United States and Canadian Academy of Pathology including the finance committee. He has a been a Director of Urologic Pathology fellowships since 1997 and his trainees practice, teach and/or conduct research in departments all over the world. Dr. Amin is the Editor-in-Chief of Advances in Anatomic Pathology since the year 2000, and serves on the editorial boards of numerous prestigious medical journals.